Please use this identifier to cite or link to this item:
|Title:||Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma|
|Authors:||Cheung, AKL;Lung, HL;Cheng, Y;Chua, D;LaiWan Kwong, D;Tsao, SW;Lung, ML;Law, EWL;Kashuba, VI;Pavlova, TV;Zabarovsky, ER;Sasaki, T;Stanbridge, EJ|
|subject:||anti-angiogenic;fibulin-2;methylation;nasopharyngeal carcinoma;tumor suppressor;VEGF|
|Publisher:||Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc|
|Description:||Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved.|
|Standard no:||Oncogene, 2012, v. 31 n. 6, p. 728-738|
|Appears in Collections:||Department of Anatomy|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.